Generics Makers Renew Battle Over Key Patent for Johnson & Johnson’s Schizophrenia Drug

In the aftermath of a Federal Circuit ruling, generics manufacturers Teva and Viatris are making renewed efforts to invalidate the final patent tied to Johnson & Johnson’s widely-used schizophrenia medication, Invega Sustenna. This ongoing legal tussle underscores the broader implications of the appeals court’s decision on pharmaceutical patent law. For more detailed insights, the original coverage can be accessed here.